Bristol Myers Squibb

CompanyUnited StatesFounded 1989

RORWikidata

Bristol Myers Squibb develops 43 assets, the furthest approved (abatacept in Active Polyarticular Juvenile Idiopathic Arthritis). Mostly small molecule and antibody acting on PPARA, DDB1 and CRBN; based in the United States, founded in 1989.

43
Assets
Furthest stage
Approved
1,084
Trials
421
Signals

Pipeline

43
  • abatacept

    Binds CD80 and CD86 to block T-cell costimulation and suppress inflammation.

    Approved, Protein or enzyme, CD80, CD86, Active Polyarticular Juvenile Idiopathic Arthritis, psoriatic arthritis

  • adagrasib

    Inhibits mutant KRAS G12C, blocking signaling that drives tumor growth.

    Approved, Small molecule, KRAS, non-small cell lung cancer, advanced non small cell lung cancer

  • Ciprofibrate

    PPARalpha agonist that modifies plasma lipids.

    Approved, Small molecule, PPARA, dyslipidemia (Phase 3), hypertension (Phase 3), Partner

40 more assets

Full company profiles: pipeline, trials, funding and people.

See Pro

Subsidiaries

6

In the full profile

  • Evidence behind the mechanisms9
  • Trials2,609
  • Deals7
  • Signals20
  • Integrity notices1
  • Similar companies6

Papers

Intelligence